HORMONAL BIOMARKERS AND MOLECULAR SUBGROUPS IN EC 153 6 Table S1. Baseline characteristics of the four previous published cohorts and one unpublished cohort ENITEC centers Vancouver cohort Van der Putten et al. 2016 Van Weelden et al. 2020 Ravaggi et al. 2022 BRNO Talhouk et al. 2015 and 2017 Study characteristics N included 305 40 94 37 263 Molecular subgroups determined by Full NGS Full NGS ProMisE ProMisE ProMisE DNA sequencing by smMIP by NGS smMIP by NGS NGS Sanger MiSeq and Sanger Order of molecular subgroup allocation according to TCGA TCGA TCGA TCGA ProMisE Median follow-up (months) 71.0 (4.0-198.0) 52.5 (2-123) 53.5 (9.0-217.0) 53.0 (6.0-129.0) 55.2 (1.0-283.0) Demographics European European European European Canadian Patient characteristic Age (years) 63.0 (34.0-93.0) 64.0 (49.0-82.0) 65.0 (31.0-90.0) 71.0 (47.0-85.0) 65.5 (35.0-93.0) Final pathologic characteristics Histology EEC 282 (92.5) 33 (82.5) 69 (73.4) 29 (78.4) 181 (68.8) NEEC 23 (7.5) 7 (17.5) 25 (26.6) 8 (21.6) 82 (31.2) Grade 1-2 234 (76.7) 27 (67.5) 17 (18.1) 21 (56.8) 95 (36.1) 3 71 (23.3) 13 (32.5) 77 (81.9) 16 (43.2) 168 (63.9) ER 0-10 27 (8.9) 7 (17.5) 34 (36.2) 6 (16.2) 68 (25.9) 20-80 151 (49.5) 23 (57.5) 37 (39.4) 13 (35.1) 130 (49.4) 90-100 127 (41.6) 10 (25.0) 16 (17.0) 18 (48.6) 65 (24.7) Missing 0 (0.0) 0 (0.0) 7 (7.4) 0 (0.0) 0 (0.0) PR 0-10 48 (15.7) 12 (30.0) 47 (50.0) 9 (24.3) 125 (47.5) 20-80 164 (53.8) 22 (55.0) 35 (37.2) 12 (32.4) 111 (42.2) 90-100 91 (29.8) 6 (15.0) 8 (8.5) 16 (43.2) 27 (10.3) Missing 2 (0.7) 0 (0.0) 4 (4.3) 0 (0.0) 0 (0.0)
RkJQdWJsaXNoZXIy MTk4NDMw